Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 80

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 80
---
istribution
to the affected tissues, and extend systemic circulation time. These enhancements may collectively improve the therapeutic index by increasing
efficacy while potentially reducing systemic exposure and associated toxicities. However, there can be no assurance that features will
be replicated in clinical studies or translate into meaningful patient outcomes.

References

| 1. | De Villiers MM, Aramwit P, Kwon GS. Nanotechnology 
 in Drug Delivery. Springer, 2008.                  |

| 2. | Allen TM, Cullis PR. Liposomal drug delivery systems:                                  
 From concept to clinical applications. Advanced Drug Delivery Revew. 2013;65(1):36–48. |

| 3. | He Q, Zhang Z, Gao F, Li Y, Shi J. In vivo biodistribution                                                                   
 and urinary excretion of mesoporous silica nanoparticles: Effects of particle size and PEGylation. Small. 2011;7(2):271–280. |

| 4. | Sercombe L, Veerati T, Moheimani F, Wu SY, Sood                                                               
 AK, Hua S. Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology. 2015;6:286. |

| 5. | EMA Assessment Report – Comirnaty (BioNTech/Pfizer). 
 EMA/707383/2020.                                     |

| 6. | Baden LR, El Sahly HM, Essink B, et al. Efficacy                                                         
 and safety of the mRNA-1273 SARS-CoV-2 vaccine. N The New England Journal of Medicine. 2021;384:403–416. |

| 7. | Arcturus Therapeutics Press Releases, 2020–2021. |

| 8. | Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles           
 for mRNA delivery. Nature Reviews Materials. 2021;6:1078–1094. |

<div align='center'>48

Product Pipeline in Development</div>

Through LipoVation,
our operating subsidiary which we acquired in July 2024, we are developing programs in infectious diseases, oncology and vaccination.

We intend to use tiny, specially designed
fat-based particles called liposomes to carry powerful medicines directly to where they’re needed in the body. We believe that
this method is one of the more advanced ways to deliver medicine and